Investigation of cisplatin-induced acute kidney injury using LC-HRMS and network pharmacology approaches in mixed Curcuma longa and Curcuma zedoaria eExtracts

利用液相色谱-高分辨率质谱和网络药理学方法研究姜黄和莪术混合提取物中顺铂诱导的急性肾损伤

阅读:1

Abstract

BACKGROUND: Cisplatin-induced acute kidney injury (AKI) is a serious complication of cancer therapy. Natural compounds, such as those found in Curcuma species, may exert protective effects through anti-inflammatory and antioxidant mechanisms. AIM: This study investigated the therapeutic mechanisms of combined Curcuma longa and Curcuma zedoaria extracts against cisplatin-induced kidney damage using Ultra-High Performance Liquid Chromatography-High Resolution Mass Spectrometry (UHPLC-HRMS) and network pharmacology. METHODS: An ethanolic extract was prepared and analyzed using UHPLC-Q-Orbitrap HRMS to identify active compounds. The antioxidant capacity was assessed using the Diphenyl-2-picryl-hydrazyl assay. Network pharmacology was used to predict compound-target interactions and identify key proteins involved in AKI pathways. RESULTS: UHPLC-Q-Orbitrap HRMS analysis identified 40 bioactive compounds, among which 22 met the OB >30% threshold. Network analysis revealed 14 overlapping protein targets associated with AKI from 485 compound-related targets and 198 disease-related targets. CONCLUSION: This study demonstrated that key phytochemicals in C. longa and C. zedoaria may act on multiple protein targets implicated in AKI, highlighting their potential as multitarget therapeutics for kidney protection and future drug development.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。